NYSE:HAE - Haemonetics Stock Price, Forecast & News

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics Co. (NYSE:HAE) posted its earnings results on Tuesday, February, 4th. The medical instruments supplier reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.76 by $0.18. The medical instruments supplier had revenue of $259 million for the quarter, compared to analysts' expectations of $255.40 million. Haemonetics had a net margin of 7.98% and a return on equity of 27.78%. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 earnings per share. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Haemonetics.

Haemonetics updated its FY 2020 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share guidance of 3.30-3.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.18. The company issued revenue guidance of $996.606M - 1.016 billion, compared to the consensus revenue estimate of $1 billion.

6 equities research analysts have issued 1-year price objectives for Haemonetics' shares. Their forecasts range from $140.00 to $150.00. On average, they expect Haemonetics' stock price to reach $144.33 in the next twelve months. This suggests a possible upside of 19.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

News headlines about HAE stock have trended somewhat negative on Tuesday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Haemonetics earned a daily sentiment score of -1.8 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Haemonetics.

Haemonetics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,270,000 shares, an increase of 25.7% from the January 15th total of 1,010,000 shares. Based on an average trading volume of 346,200 shares, the days-to-cover ratio is presently 3.7 days. Approximately 2.5% of the company's shares are sold short. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Antares Pharma (ATRS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Apache (APA), Zoetis (ZTS), NVIDIA (NVDA), Pfizer (PFE), Micron Technology (MU), Nexstar Media Group (NXST) and Citigroup (C).

Haemonetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital Research Global Investors (5.36%), Renaissance Technologies LLC (4.85%), FMR LLC (4.22%), Jackson Square Partners LLC (3.54%), State Street Corp (3.26%) and Franklin Resources Inc. (2.03%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AQR Capital Management LLC, Man Group plc, Eagle Asset Management Inc., PNC Financial Services Group Inc., Russell Investments Group Ltd., Castleark Management LLC and State of Tennessee Treasury Department. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Capital Research Global Investors, Westfield Capital Management Co. LP, Credit Suisse AG, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Jackson Square Partners LLC and UBS Group AG. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $120.38.

Haemonetics has a market capitalization of $6.05 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]